Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
TO FIX THE FDA APPROVAL’S FLAW
By Staff Reporters
***
***
DEFINITION: Right-to-try laws are United States state laws and a federal law that were created with the intent of allowing terminally ill patients access to experimental therapies (drugs, biologics, devices) that have completed Phase I testing but have not been approved by the Food and Drug Administration (FDA).
Right to Try 2.0 laws could help fix FDA’s approval process; Right to Try for Individualized Treatments.
This law would allow patients suffering from rare and genetic diseases to try personalized treatments not yet approved by the FDA, as long as they have the support of their physician and have exhausted other treatment options. This policy would have an outsized impact on patients with rare diseases. Although rare diseases have small patient pools by definition, collectively, about 30 million Americans are estimated to have a rare disease.
What’s more, 80% of these rare diseases are genetic in nature, and 95% have no FDA-approved treatment.
COMMENTS APPRECIATED
Thank You
***
***
Share this:
Filed under: "Doctors Only", Drugs and Pharma, Ethics, Health Economics, Health Insurance, Industry Indignation Index, Information Technology | Tagged: Drugs, FDA, medications, rare disease, right to try, right to try laws | Leave a comment »
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 